Mycophenolic acid-induced GTP depletion also affects ATP and pyrimidine synthesis in mitogen-stimulated primary human T-lymphocytes

Transplantation

Volumn 69, Issue 5, 2000, Pages 890-897

  Qiu, Ying ^a,b   Fairbanks, Lynette D ^a   Rückemann, Katarzyna ^a,c   Hawrylowicz, Catherine M ^a   Richards, David F ^a   Kirschbaum, Bernhard ^d   Simmonds, H Anne ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BICARBONATE; GLYCINE; GUANOSINE TRIPHOSPHATE; HYPOXANTHINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHYTOHEMAGGLUTININ; PYRIMIDINE NUCLEOTIDE; URIDINE;

ARTICLE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; METABOLIC INHIBITION; PRIORITY JOURNAL; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; T LYMPHOCYTE SUBPOPULATION;

EID: 0034654108     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200003150-00038     Document Type: Article

References (38)

1. Allison AC, Hovi T, Watts RWE, Webster ADB. The role of de novo purine synthesis in lymphocyte transformation: purine and pyrimidine metabolism. Ciba Found Symp 1977; 48: 207.
2. Hovi T, Allison AC, Raivio K, Vaheri A. Purine metabolism and the control of cell proliferation: purine and pyrimidine metabolism. Ciba Found Symp 1977; 48: 225.
3. Garcia RC, Leoni P, Allison AC. Control of phosphoribosyl pyrophosphate synthesis in human lymphocytes. Biochem Biophys Res Comm 1977; 77: 1067.
4. Eugui EM, Almquist SJ, Müller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161.
5. Eugui EM, Allison AC. Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs Transplant Proc 1993; 25(suppl 2): 8.
6. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug mycophenolate mofetil. Immunol Rev 1993; 136: 1.
7. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block glycosylation of adhesion molecules. Transplant Proc 1993; 25: 67.
8. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide (and its malononitriloamide analogs). Curr Opin Immunol 1996; 8: 710.
9. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
10. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded randomized clinical trial of mycophenolate mofetil for prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
11. Halloran P, Mathew T, Tomlanovich S, et al. For the international mycophenolate mofetil renal transplant study group. Mycophenolate mofetil in renal allograph recipients. Transplantation 1997; 63: 39.
12. Glicklich D, Gupta B, Schurter-Frey G, Greenstein SM, Schechner RS, Tellis VA. Chronic renal allograph rejection. No response to mycophenolate mofetil. Transplantation 1998; 66: 398.
13. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969; 113: 515.
14. Lowe JK, Brox L, Henderson JF. Consequences of Inhibition of Guanine Nucleotide Synthesis by Mycophenolic Acid and Virazole. Cancer Res 1977; 37: 736.
15. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterisation of human Type 1 and Type 11 IMP dehydrogenases. J Biol Chem 1993; 27286.
16. Dayton JS, Lindsten T, Thompson CB, Mitchell BS. Effects of T-lymphocytes activation on inosine monophosphate dehydrogenase expression. J Immunol 1994; 152: 984.
17. Fairbanks LD, Bofill M, Rückemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans: disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995; 270: 29682.
18. Makowka L, Chapman F and Cramer DV. Historical development of brequinar sodium as an new immunosuppressive drug for transplantation. Transplant Proc Suppl 2 1993; 25: 2.
19. Cramer DV. Brequinar Sodium. Transplant Proc 1996;960.
20. Tu Y, Stepkowski SM, Chou T-C, Kahan BD. The synergistic effects of cyclosporine, sirolimus and brequinar on heart allograft survival in mice. Transplantation. 1995; 59: 177
21. Silva HT Jr, Gao W, Shorthouse RA, Löffier M, Morris RE. In vitro and in vivo effects of leflunomide, brequinar and cyclosporine on pyrimidine biosynthesis. Transplant Proc 1997; 29: 1292.
22. Silva HT Jr, Morris RE. Drug evaluation. Pulmonary-allergy, dermatological, gastrointestinal and arthritis: leflunomide and malonitriles. Exp Opin Invest Drugs 1997; 6: 51.
23. Rückemann K, Fairbanks LD, Hawrylowicz CM, Richards DF, Kirschbaum B, Simmonds HA. Leflunomide inhibits pyrimidine synthesis de novo in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998; 273: 21682.
24. Elli A, Aroldi A, Montagnino G, Tarantino A, Ponticelli C. Mycophenolate mofetil and cough. Transplantation 1998; 66: 409.
25. Seebacher G, Mallinger R, Laufer G et al. Pharmacokinetics of mycophenolate mofetil in heart transplant recipients. Adv Exp Med Biol 1998; 431: 801-80335
26. Shaw SM, Carrey EA. Regulation of the mammalian carbamoylphosphate synthetase II by effectors and phosphorylation. Eur J Biochem 1992; 207: 957.
27. Bokkerink JPM, De Abreu RA, Bakker MAH, Hulscher TW, van Baal JM, De Vaan GAm Dose-related effects of methotrexate on purine and pyrimidine nucleotides and on cell kinetic parameters in MOLT-4 malignant human T-lymphoblasts. Biochem Pharmacol 1986; 35: 3557
28. Platz KP, Sollinger HW, Hullett DA, Eckoff DE, Eugui EM, Allison AC. RS-61443 - a new potent immunosuppressive agent. Transplantation 1991; 51: 027.
29. Wilson BS, Deanin GG, Standefer JC, Vanderjagt D, Oliver JM. Depletion of guanine nucleotides with mycophenolic acid suppresses IgE receptor-mediated degranulation of rat basophilic leukaemia cells. J Immunol 1989; 143: 259.
30. Kugichi K, Collart FR, Henning-Chubb C, Huberman E. Cell differentiation and altered IMPDH expression induced in human T-lymphoblastoid leukaemia cells by mycophenolic acid and Tiazofurin. Exp Cell Res 1990; 187: 47.
31. Barankiewicz J, Cohen A. Purine nucleotide metabolism in phytohaemagglutin-induced human T-lymphocytes. Arch Biochem Biophys 1987; 258: 167.
32. Sokolowski JA, Sartorelli AC. Inhibition of mannose incorporation into glycoproteins and dolichol-linked intermediates of sacrcoma 180 cells by 6-mercaptopurine ribonucleoside Int J Cancer 1987; 39: 764.
33. Geijessen GJ, Pieters R, Veerman AJP, Pinedo HM, Peters GJ. Do inhibitors of IMPDH have a future in cancer chemotherapy. Int J Pur Pyrimidine Res 1991; 2: 17.
34. Hrabak A, Spasokukotskaja T, Temesi A, Staub M. The salvage of deoxycytidine into dCDP-diacylglycerol by macrophages and lymphocytes. Biochem Biophys Res Commun 1993; 193: 212.
35. Lazo JS, Shansky CW, Sartorelli AC. Reduction in cell surface concavalin A binding and mannose incorporation into glycoproteins of sarcoma 180 by 6-thioguanine. Biochem Pharmacol 1979; 28: 583..
36. Stet EH, De Abreu RA, Janssen YPG, Bökkerink JPM, Trijbels FJM. A biochemical basis for the synergism of 6-mercaptopurine and mycophenolic acid in Molt F4, a human malignant lymphoblast line. Biochim Biophys Acta 1993; 1180: 277.
37. Rückemann K, Laurence A, Fairbanks LD et al. Biochemical basis for the impaired immune response in chronic renal failure? Adv Exp Med Biol 1998; 431: 559.
38. Iu I, Gricschtein IV, Osetrov V, Tereshenko VP. The morpho-functional instability of the lymphocyte membrane in patients with chronic kidney failure. Urol Nefrol (Mosk)1993; 6: 46.